Early Access to Medicines Scheme in Bahrain

How the early access to medicines scheme pathway operates in Bahrain.

About Early Access to Medicines Scheme

UK MHRA's pathway for early access to promising unlicensed medicines.

How Early Access to Medicines Scheme works in Bahrain

Bahrain's NHRA accepts named-patient import requests for rare-disease and specialty drugs not registered locally.

Patients in Bahrain seeking access under Early Access to Medicines Scheme typically follow this flow: a licensed physician in Bahrain issues the prescription and clinical justification, the regulator reviews and authorises, and an authorised operator coordinates import.

Documents required in Bahrain

  • Physician prescription and clinical-justification letter.
  • Patient identification and consent.
  • Country-specific NPP/personal-import form.
  • Hospital or clinic attestation where required.

Typical timeline

End-to-end 2-6 weeks in most tier 2 jurisdictions. Cellular and gene therapies may require additional ethics-committee review.

Start a request

Start a request under Early Access to Medicines Scheme in Bahrain

AI disclosure & medical review. Content on this page is reviewed by Reserve Meds's AI clinical and regulatory review agents. A US-licensed human pharmacist (sourced through Altima Care, a US-licensed specialty wholesaler) reviews every prescription before dispensing. Regulatory posture is AI-summarized and not legal advice; case-specific questions route to retained outside counsel. Last medically reviewed: .
WhatsApp